Previously, we reported that dual targeting EGFR with a monoclonal antibody (cetuximab) and TKI (afatinib or osimertinib) led to sustained tumor control in patients with EGFR 20ins-positive NSCLC9,10. This evidence concerns the gene EGFR and neoplasm.